Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720443 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04720443: Completed Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.
NCT04720443 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that has completed, run by The National Institutes of Pharmaceutical R&D Co. Ltd, China. The registered enrollment target is 56 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04720443, a Phase 1 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
Primary Outcome
The AEs developed during or after the study treatment (as treatment-emergent adverse event \[TEAE\]) will be summarized by preferred term, system organ class, severity, and relationship to the investigational product.
Conditions Studied
Interventions
- DRUG NIP292 tablet
Study Locations (1)
California
- PAREXEL International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-11-22 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 1 |
What the finished NCT04720443 record still lists
NCT04720443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which NIP292 tablet is the first listed.
NCT04720443 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04720443 about?
NCT04720443 is a clinical study titled "A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects". This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
What is the current status of trial NCT04720443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-11-22. Estimated completion is 2022-07-14.
What conditions does trial NCT04720443 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT04720443?
The interventions under investigation include: NIP292 tablet (DRUG).
Who is sponsoring clinical trial NCT04720443?
This trial is sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04720443 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04720443's enrollment target sits among peer trials
56 31st of 51 higher than 21 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI